The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
Open accessAbstract
Purpose: Antibody-based cancer therapies have emerged as the most promising therapeutics in oncology. The purpose of this study was to discover novel targets for therapeutic antibodies in solid cancer. Experimental Design: We combined data mining and wet-bench experiments to identify strictly gastrocyte lineage–specific cell surface molecules and to validate them as therapeutic antibody targets. Results: We identified isoform 2 of the tight junction molecule claudin-18 (CLDN18.2) as a highly selective cell lineage marker. Its expression in normal tissues is strictly confined to differentiated epithelial cells of the gastric mucosa, but it is absent from the gastric stem cell zone. CLDN18.2 is retained on malignant transformation and is expressed in a significant proportion of primary gastric cancers and the metastases thereof. In addition to its orthotopic expression, we found frequent ectopic activation of CLDN18.2 in pancreatic, esophageal, ovarian, and lung tumors, correlating with distinct histologic subtypes. The activation of CLDN18.2 depends on the binding of the transcription factor cyclic AMP–responsive element binding protein to its unmethylated consensus site. Most importantly, we were able to raise monoclonal antibodies that bind to CLDN18.2 but not to its lung-specific splice variant and recognize the antigen on the surface of cancer cells. Conclusions: Its highly restricted expression pattern in normal tissues, its frequent ectopic activation in a diversity of human cancers, and the ability to specifically target this molecule at the cell surface of tumor cells qualify CLDN18.2 as a novel, highly attractive pan-cancer target for the antibody therapy of epithelial tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Multifunctional strands in tight junctions
Tsukita, S., Furuse, M., & Itoh, M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35067088 · Cited by 2,509
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10<2049::aid-cncr1>3.0.co;2-2 · Cited by 2,115
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A., Chen, Y.-T., & Old, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1669 · Cited by 1,582
Zhang, X., Odom, D. T., Koo, S.-H., Conkright, M. D., Canettieri, G., Best, J., Chen, H., Jenner, R., Herbolsheimer, E., Jacobsen, E., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501076102 · Cited by 992
Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer
Dhawan, P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24543 · Cited by 566
Iguchi-Ariga, S. M., & Schaffner, W. (1989) · Genes & Development · doi:10.1101/gad.3.5.612 · Cited by 559
Hough, C. D., Sherman‐Baust, C. A., Pizer, E. S., Montz, F. J., Im, D. D., Rosenshein, N. B., Cho, K. R., Riggins, G. J., & Morin, P. J. (2000) · PubMed · Cited by 502
The claudin gene family: expression in normal and neoplastic tissues
Hewitt, K. J., Agarwal, R., & Morin, P. J. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-186 · Cited by 497
The changing epidemiology of esophageal cancer.
Blot, W. J., & McLaughlin, J. K. (1999) · PubMed · Cited by 484
Cited by
Gastric cancer treatment: recent progress and future perspectives
Guan, W.-L., He, Y., & Xu, R.-H. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01451-3 · Cited by 944
Shitara, K., Lordick, F., Bang, Y.-J., Enzinger, P., Ilson, D., Shah, M. A., Van Cutsem, E., Xu, R.-H., Aprile, G., Xu, J., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00620-7 · Cited by 822
Shah, M. A., Shitara, K., Ajani, J. A., Bang, Y.-J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., Gallego Plazas, J., Huang, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02465-7 · Cited by 681
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Reinhard, K., Rengstl, B., Oehm, P., Michel, K., Billmeier, A., Hayduk, N., Klein, O., Kuna, K., Ouchan, Y., Wöll, S., et al. (2020) · Science · doi:10.1126/science.aay5967 · Cited by 512
Self-citationSundar, R., Nakayama, I., Markar, S. R., Shitara, K., van Laarhoven, H. W. M., Janjigian, Y. Y., & Smyth, E. C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00052-2 · Cited by 393
Metadata
- Authors
- Sahin, U., Koslowski, M., Dhaene, K., Usener, D., Brandenburg, G., Seitz, G., Huber, C., & Türeci, O.
- Venue
- Clinical Cancer Research
- Published
- 2008-12-01
- Volume
- 14
- Issue
- 23
- Pages
- 7624-7634
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2108902851
- Cited by
- 501
- References
- 34
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-1547
- The paper
- Sahin, U., Koslowski, M., Dhaene, K., Usener, D., Brandenburg, G., Seitz, G., Huber, C., & Türeci, O. (2008). Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-1547
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.